CastleArk Alternatives’s Medtronic MDT Stock Holding History

CastleArk Alternatives’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-480	Closed	-$60K	–	175
2021 Q3	$60K	Buy	+480	New	+$62.1K	﹤0.01%	318

Other funds holding MDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

CastleArk Alternatives's MDT Position: Q4 2021 in Review

CastleArk Alternatives sold out of Medtronic (MDT) in Q4 2021, closing a stake of 480 shares — an estimated $60K sold.

CastleArk Alternatives first reported a position in MDT in Q3 2021 and held it in 1 quarter. The position peaked at $60K in Q3 2021. 2,059 funds tracked by Wall St. Rank hold MDT as of Q4 2021.

CastleArk Alternatives reported no remaining Medtronic position as of Q4 2021 after selling out during the quarter.
CastleArk Alternatives sold 480 Medtronic shares in Q4 2021, an estimated $60K.
CastleArk Alternatives first reported a position in Medtronic in Q3 2021 and held it in 1 quarter.
CastleArk Alternatives's Medtronic position peaked at $60K in Q3 2021.
2,059 funds tracked by Wall St. Rank held Medtronic as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.